

ORYZON receives a new 1.14 M USD public grant to explore new indications for epigenetic inhibitors

❖ Within a consortium, led by Oryzon, that will have a 1.7 M USD aggregated budget

MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, December 11, 2018 – Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the company has been granted a preferential 10 year-term loan with a three-year grace period at 0% interest by the Ministry of Science, Innovation and Universities, Government of Spain, and FEDER Funds from the European Union. Thanks to this loan, Oryzon will receive approximately 1.14 M USD (in multiyear disbursements) for further development of its epigenetic inhibitors in combination with other available drugs against oncologic indications.

This grant (RTC-2017-6407-1) will cover the partial funding of a project entitled “Evaluation and proof of concept of the effectiveness of ORY-1001 in combination therapies in oncological indication (COMBO-EPoC)”, which is currently being carried out under the leadership of Oryzon in collaboration with various well renowned academic institutions such as the Technological Center LEITAT (Barcelona), the Fundación Privada Institut d’Investigació Oncològica de Vall-Hebron (VHIO) (Barcelona), and the Fundación para la Investigación Hospital Universitario La Fe (ISSLaFe) (Valencia). The project has a 36 month duration, starting January 1, 2018 and ending December 31, 2020, and the aggregated budget for the project is approximately 1.7M USD. The public institutions will receive a non-reimbursable grant for a total amount exceeding 0.5 M USD to carry out different activities to assess the potential of Oryzon’s drugs in oncological indications.

Carlos Buesa, Oryzon’s Chief Executive Officer, commented: “We have seen a few days ago at ASH and recently at other oncology clinical conferences the importance of combination therapies. COMBO-EPoC is precisely designed to explore the therapeutic potential of Iadademstat (ORY-1001) and other of our proprietary epigenetic inhibitors, combining them with the best treatments currently available in oncological diseases. Our first two Phase IIa clinical trials in acute leukemia (ALICE study) and in small cell lung cancer (CLEPSIDRA) are an example of this.”

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon's LSD1 program has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com

FORWARD-LOOKING STATEMENTS

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates" and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon's securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

US Contact:**The Trout Group****Thomas Hoffmann**

+1 646 378 2932

thoffmann@troutgroup.com**Spain:****ATREVIA****Patricia Cobo**

+34 91 564 07 25

pcobo@atrevia.com**Oryzon:****Emili Torrell****BD Director**

+34 93 515 13 13

etorrell@oryzon.com